BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

  January 27, 2026

   · 

  2 min read
• Press Releases

  Alps Dx and Hamilton Company Announce Showcase of Alps Dx Atelier at SLAS 2026, an Automated Preanalytical System for Oral Fluid Workflows

  January 27, 2026

   · 

  4 min read
• 

  JPM

  JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute

  With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.

  January 27, 2026

   · 

  6 min read

   · 

  Annalee Armstrong
• Press Releases

  Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

  January 27, 2026

   · 

  7 min read
• Press Releases

  Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

  January 27, 2026

   · 

  7 min read
• Press Releases

  Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

  January 27, 2026

   · 

  6 min read
• Press Releases

  IBA signs contract for a Proteus®ONE proton therapy system to be located at the MacKay Memorial Hospital in New Taipei City, Taiwan

  January 27, 2026

   · 

  3 min read
• Press Releases

  [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

  January 27, 2026

   · 

  6 min read
• Press Releases

  Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

  January 27, 2026

   · 

  4 min read
• Press Releases

  Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

  January 27, 2026

   · 

  4 min read